Monoclonal antibodies (mAbs) have proven to be useful for development of new therapeutic
drugs and diagnostic techniques. To overcome the difficulties posed by their complex …

Antibody-drug conjugates (ADCs) are innovative biopharmaceutical products in which a
monoclonal antibody is linked to a small molecule drug with a stable linker. Most of the …

Antibody–drug conjugates (ADCs) are one of the fastest growing classes of oncology
therapeutics. After half a century of research, the approvals of brentuximab vedotin (in 2011) …

Aggregation of human therapeutic antibodies represents a significant hurdle to product
development. In a test across multiple antibodies, it was observed that IgG1 antibodies …

Therapeutic antibodies of many different IgG subclasses (IgG1, IgG2 and IgG4) are used in
the treatment of various cancers, rheumatoid arthritis and other inflammatory and infectious …

Monoclonal antibodies are the fastest growing class of biologics in the pharmaceutical
industry. The correlation between mAb glycosylation and aggregation has not been …

Antibody drug conjugates (ADCs) have emerged as an important pharmaceutical class of
drugs designed to harness the specificity of antibodies with the potency of small molecule …

Antibodies are uniquely suited to serve essential roles in the human immune defense as
they combine several specific functions in one hetero-oligomeric protein. Their constant …

Conventional antibody–drug conjugates (ADCs) are heterogeneous mixtures of chemically
distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal …

Monomeric and aggregated states of an IgG1 antibody were characterized under acidic
conditions as a function of solution pH (3.5–5.5). A combination of intrinsic/extrinsic …